Tarsus Pharmaceuticals, Inc. (TARS) Stock Price & How to Invest
Short answer
Tarsus Pharmaceuticals (Nasdaq: TARS) is a commercial-stage eye-care biopharma built almost entirely around XDEMVY, the first FDA-approved drug for Demodex blepharitis. Investing in it means betting on one fast-growing but single-product franchise, so the picture rides on XDEMVY's continued prescription growth, its reimbursement setup, and how a recent short-seller allegation about copay practices plays out.
TARS stock price
As of 2026-07-08, Tarsus Pharmaceuticals, Inc. (TARS) last closed at $67.73, up 64.0% over the past year. Over the past 52 weeks it has traded between $38.82 and $82.51.
Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Tarsus Pharmaceuticals, Inc.'s investor relations page. Walnut is informational, not investment advice.
What does Tarsus Pharmaceuticals, Inc. (TARS) do?
Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company focused on therapeutic eye care. Its business is anchored by XDEMVY (lotilaner ophthalmic solution 0.25%), the first and only FDA-approved treatment that directly targets the Demodex mites behind Demodex blepharitis, a common and previously under-treated eyelid condition. The company delivered roughly 400,000 bottles of XDEMVY in 2025 (up from about 163,000 in 2024) and is building a lotilaner-based pipeline that includes TP-04 for ocular rosacea and TP-05 for potential prevention of Lyme disease, with topline data for both expected in the first half of 2027.
The investment picture is a classic single-product growth story. XDEMVY net product sales grew more than 85% year over year in the first quarter of 2026, gross margins run around 93%, and management targets more than $2 billion in eventual peak sales, yet the company still runs near breakeven and depends heavily on one drug. In late June 2026, short-seller Culper Research disclosed a short position and alleged that XDEMVY sales lean on an improper Medicare copay-assistance arrangement and that the addressable market is far smaller than the company claims, which added a new layer of controversy on top of the usual biopharma reimbursement and competition risks.
What's driving Tarsus Pharmaceuticals, Inc. (TARS)?
1. XDEMVY prescription growth
XDEMVY net product sales rose more than 85% year over year in Q1 2026 to about $145 million, driven by expanding prescriber adoption and direct-to-consumer campaigns. Management reaffirmed full-year 2026 guidance of roughly $670 to $700 million in net product sales. The core question is how long high double-digit growth can persist as the easiest-to-reach prescribers are converted.
2. Large, under-penetrated indication
Demodex blepharitis is estimated to affect tens of millions of Americans, and XDEMVY remains the only FDA-approved therapy that targets the underlying mites. Tarsus frames a path to more than $2 billion in peak sales on the back of that penetration runway. A short-seller has publicly disputed the size of the realistic addressable market, so this driver is also contested.
3. High-margin economics
XDEMVY carries gross margins around 93%, and the Q1 2026 net loss narrowed sharply to about $7 million from roughly $25 million a year earlier as revenue scaled against a largely fixed commercial base. If growth continues without a matching rise in selling and marketing spend, operating leverage could push the company toward sustained profitability.
4. Pipeline optionality
Beyond XDEMVY, Tarsus is advancing TP-04 for ocular rosacea and TP-05, an oral tablet studied for Lyme disease prevention, both using the same lotilaner molecule. Topline data for these Phase 2 programs is expected in the first half of 2027. Success would diversify a currently one-product company, though these are early-stage and carry standard clinical risk.
What are the risks to Tarsus Pharmaceuticals, Inc. (TARS)?
The overwhelming risk is single-product concentration: essentially all revenue comes from XDEMVY, so any slowdown in prescriptions, coverage, or pricing hits the whole company. In late June 2026, short-seller Culper Research alleged that XDEMVY sales depend on donations routed to a blepharitis copay fund in a way it argues may violate the federal Anti-Kickback Statute, and it claimed the true addressable market is roughly a fifth of company estimates; these are unproven allegations, but they introduce regulatory, reimbursement, and reputational uncertainty. Tarsus also depends on intellectual property licensed from Elanco, faces gross-to-net and Medicare Part D dynamics that can compress net pricing, and still runs near breakeven with a history of losses. Cheaper off-label alternatives and potential future competitors, plus binary Phase 2 pipeline readouts, round out the risk set.
How is Tarsus Pharmaceuticals, Inc. (TARS) valued? (approximate, JULY 2026)
A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Tarsus Pharmaceuticals, Inc.'s investor relations page or your broker.
- Revenue (TTM): ~$540M
- XDEMVY sales (FY2025): ~$451M
- Q1 2026 revenue: ~$162M
- FY2026 sales guidance: ~$670-700M
- Market cap: ~$2.9B
- Cash & marketable securities: ~$417M
As of July 2026 TARS traded near $67 with a market capitalization around $2.9 billion, valuing the company at several times trailing revenue on a still-unprofitable base. That multiple reflects expectations of continued high XDEMVY growth toward the company's stated peak-sales ambitions. The recent short-seller report contributed to share-price volatility and directly challenges the growth and market-size assumptions embedded in the valuation.
Who competes with Tarsus Pharmaceuticals, Inc. (TARS)?
Off-label and procedural alternatives
Because XDEMVY is the only FDA-approved Demodex blepharitis drug, its practical competition is largely non-pharmaceutical: tea tree oil lid scrubs, hypochlorous acid cleansers, compounded ivermectin or metronidazole, and in-office procedures like BlephEx and IPL. These are cheaper and familiar to eye-care providers, though studies show lower Demodex eradication than XDEMVY.
Broader ophthalmology and dry-eye franchises
Large eye-care players such as AbbVie (Allergan), Bausch + Lomb, Alcon, and Harrow compete for the same ophthalmologist and optometrist attention and prescribing budget with dry-eye and lid-margin products, even where they do not directly treat Demodex mites. They have deeper commercial infrastructure and existing payer relationships.
Future pipeline entrants
The commercial success of XDEMVY invites potential future competition in Demodex blepharitis and adjacent lid diseases, and Tarsus's own pipeline candidates (TP-04, TP-05) will eventually face established players in ocular rosacea and Lyme prevention. New FDA-approved rivals would erode XDEMVY's current sole-approved-therapy advantage.
How to invest in Tarsus Pharmaceuticals, Inc. (TARS)
There are three common ways to get TARS exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so TARS sits alongside other stocks that express the same thesis.
Walnut takes the basket route. Describe a thesis where TARS fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.
The bottom line on Tarsus Pharmaceuticals, Inc. (TARS)
TARS is a rapidly scaling single-drug eye-care story where the upside case rests on XDEMVY reaching blockbuster sales and the risk case rests on that same concentration plus fresh questions about how those sales are funded.
More on Tarsus Pharmaceuticals, Inc. (TARS)
Whether TARS is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is TARS a buy?, and where the stock could go from here in the TARS stock forecast.
For income investors, whether TARS pays a dividend and how the payout looks is covered in does TARS pay a dividend?
Build a basket around TARS with Walnut
Use Tarsus Pharmaceuticals, Inc. as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What does Tarsus Pharmaceuticals do?
+
Tarsus is a commercial-stage biopharmaceutical company focused on eye care. Its main product, XDEMVY, is the first FDA-approved treatment for Demodex blepharitis, a common eyelid condition caused by mites. It is also developing lotilaner-based candidates for ocular rosacea and Lyme disease prevention.
How does Tarsus make money?
+
Almost all revenue comes from XDEMVY net product sales, supplemented by smaller license and collaboration revenue. In Q1 2026 the company reported about $162 million in total revenue, of which roughly $145 million was XDEMVY. Full-year 2025 XDEMVY sales were about $451 million.
Is Tarsus Pharmaceuticals profitable?
+
Not consistently. The company has a history of losses, though its Q1 2026 net loss narrowed to about $7 million from roughly $25 million a year earlier as XDEMVY revenue scaled against high (about 93%) gross margins. Whether it reaches sustained profitability depends on continued growth versus commercial spending.
What is XDEMVY and why does it matter to the stock?
+
XDEMVY (lotilaner ophthalmic solution) is the only FDA-approved drug that targets the Demodex mites behind Demodex blepharitis. It generates essentially all of Tarsus's revenue, so the stock's direction is closely tied to XDEMVY prescription growth, reimbursement, and peak-sales potential.
What is the short-seller report about Tarsus?
+
In late June 2026, Culper Research disclosed a short position and alleged that XDEMVY sales rely on an improper Medicare copay-assistance arrangement that it argues may breach the Anti-Kickback Statute, and that the addressable market is much smaller than the company claims. These are unproven allegations, and the company disputes such framing, but they added uncertainty and volatility.
Who are Tarsus Pharmaceuticals' competitors?
+
XDEMVY has no direct FDA-approved pharmaceutical competitor for Demodex blepharitis. Its practical competition includes off-label options like tea tree oil scrubs and compounded ivermectin, procedures such as BlephEx and IPL, and broader eye-care franchises from AbbVie, Bausch + Lomb, and Alcon competing for prescriber attention.
How big could XDEMVY get?
+
Management has framed a path to more than $2 billion in eventual peak annual sales, citing tens of millions of potential Demodex blepharitis patients in the US. That figure is an internal target, not a guarantee, and a short-seller has publicly argued the realistic market is far smaller.
What is the biggest risk with TARS stock?
+
Single-product concentration is the core risk: XDEMVY drives essentially all revenue, so any setback in prescriptions, payer coverage, pricing, or the recent copay-practice allegations could hit the whole company. Reliance on licensed IP, near-breakeven finances, and binary pipeline readouts add further risk. Walnut is not an investment adviser.
Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Tarsus Pharmaceuticals, Inc.'s investor relations page or your broker before making investment decisions.